Business Wire

Hillstone Networks Receives “Customers’ Choice” Distinction in Gartner® Peer Insights™ “Voice of the Customer” Network Firewalls Report for the 3rd Consecutive Year

11.5.2022 09:00:00 EEST | Business Wire | Press release

Share

Hillstone Networks, a leading provider of infrastructure protection solutions, today announced it has received “Customers’ Choice” distinction in the 2022 Gartner Peer Insights ‘Voice of the Customer’: Network Firewalls. “Gartner Peer Insights is a free peer review and rating platform designed for enterprise software and services decision makers.”

In the report, vendors, including Hillstone Networks, “placed in the upper-right quadrant of the 'Voice of the Customer' quadrants are recognized with the Gartner Peer Insights Customers’ Choice distinction, denoted with a Customers’ Choice badge. The recognized vendors meet or exceed both the market average Overall Rating and the market average User Interest and Adoption.”

“In addition to delivering innovative, proven, and effective network security solutions, Hillstone Networks is committed to providing a superior customer experience,” said Tim Liu, co-founder & CTO, of Hillstone Networks. “To be recognized with a ‘Customers’ Choice’ distinction, we believe, is a testament to our commitment to provide the exceptional service and support our customers need to keep their companies safe.”

Key findings for Hillstone Networks in the Gartner Peer Insights “Voice of the Customer” Network Firewalls report as of 28th Feb 2022 include:

  • Hillstone Networks received a 100 percent “willingness to recommend” rating from its users.
  • 85 percent of surveyed Hillstone users gave the company a 5 out of 5 stars rating.
  • Hillstone Networks’ Support Experience received a 4.9 out of 5 rating based on 94 reviews.
  • Hillstone Networks’ Sales Experience received a 4.9 out of 5 rating based on 93 reviews.

To read the 2022 Gartner Peer Insights “Voice of the Customer” Network Firewalls report, click here.

With over 23,000 global customers, Hillstone Networks has established a reputation of “security that works.” Its intuitive solutions span SD-WAN, ZTNA, Microsegmentation, CWPP, NDR, as well as XDR. Hillstone Networks has been named a Visionary in the Gartner Magic Quadrant™ for Network Firewalls and has also been recognized for eight consecutive years.

Gartner, Gartner Peer Insights ‘Voice of the Customer’: Network Firewalls, Peer Contributors, 29th April 2022. *

Gartner, Magic Quadrant for Network Firewalls, By Rajpreet Kaur, Jeremy D'Hoinne, Nat Smith, Adam Hils, 1 November 2021

Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved

About Gartner Peer Insight

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Peer Insights is a trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.

About Hillstone Networks

Hillstone Networks’ proven Infrastructure Protection solutions provide enterprises and service providers with the visibility and intelligence to comprehensively see, thoroughly understand, and rapidly act against multilayer, multistage cyberthreats. Favorably rated by leading analysts and trusted by global companies, Hillstone protects from the edge to cloud with improved total-cost-of-ownership. To learn more visit www.hillstonenet.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Zeyao Hu
+1 4085086750
inquiry@hillstonenet.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye